N,N-二乙基-2-哌啶甲胺 | 64168-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N,N-二乙基-2-哌啶甲胺
• 英文名称: 2-<(diethylamino)methyl>piperidine
• 英文别名: D,L-2-[(diethylamino)methyl]piperidine；2-[(diethylamino)methyl]piperidine；(2S)-2-diethylaminomethyl piperidine；2-[(diethylamino)methyl]piperdine；N-ethyl-N-(piperidin-2-ylmethyl)ethanamine
• CAS: 64168-09-8
• 化学式: C₁₀H₂₂N₂
• mdl: MFCD00085578
• 分子量: 170.298
• InChiKey: WTIYGHQFUHZRDA-UHFFFAOYSA-N

物化性质

• 沸点：
  218.3±8.0 °C(Predicted)
• 密度：
  0.865±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  N,N-二乙基-2-哌啶甲胺 在 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 生成 11-((2-((二乙氨基)甲基)-1-哌啶基)乙酰基)-5,11-二氢-(6H)-吡啶并[2.3-b][1.4]苯并二氮杂-6-酮
  参考文献：
  名称：

  Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics

  摘要：

  On the basis of the cardioselective muscarinic receptor antagonist AF-DX 116 (2), a series of 11-substituted pyridobenzodiazepinones (9-35) was prepared and screened for their binding affinity to muscarinic receptors located in cardiac (M2) and glandular (M3) tissue. The ratio of IC50 values of the test compounds in the two different tissues was taken as a measure of cardiac (M2) receptor selectivity. Qualitative structure-selectivity relationships point to the fact that it is the spatial orientation of the protonated side-chain nitrogen atom in relation to the tricycle that is the main determinant for receptor subtype recognition and hence is important for the achievement of cardiac (M2) selectivity.

  DOI：

  10.1021/jm00128a008
• 作为产物：
  描述：

  N,N-diethylpiperidine-2-carboxamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 N,N-二乙基-2-哌啶甲胺
  参考文献：
  名称：

  2-氨基甲基哌啶类化合物作为新型尿紧张素-II受体拮抗剂。

  摘要：

  已经发现了一系列2-氨基甲基哌啶作为新型尿素-II受体拮抗剂。描述了合成，初始结构-活性关系以及初始命中的优化，从而确定了有效的，跨物种活性和功能性尿紧张素-II受体拮抗剂，例如1a和11a。

  DOI：

  10.1016/j.bmcl.2008.03.078
• 作为试剂：
  描述：

  5,11-二氢-11-氯乙酰基-6H-吡啶并[2.3-b][1,4]苯并二氮卓-6-酮 、 N,N-二乙基-2-哌啶甲胺 在 N,N-二乙基-2-哌啶甲胺 作用下， 以62的产率得到11-((2-((二乙氨基)甲基)-1-哌啶基)乙酰基)-5,11-二氢-(6H)-吡啶并[2.3-b][1.4]苯并二氮杂-6-酮
  参考文献：
  名称：

  J. Med. Chem. 1989, 32, 1718-1724

  摘要：

  DOI：

文献信息

• Condensed diazepinones, their compositions and methods of use as
  申请人：Dr. Karl Thomae GmbH

  公开号：US04550107A1

  公开（公告）日：1985-10-29

  Disclosed are novel condensed diazepinones of formula I ##STR1## wherein B is a fused ring selected from ##STR2## X is --CH-- or, when B is ortho-phenylene, X can also be nitrogen; A.sub.1 is C.sub.1 -C.sub.2 alkylene; A.sub.2 is C.sub.1 -C.sub.2 when it is in the 2-position relative to the saturated heterocyclic ring nitrogen or a single bond or methylene when it is in the 3- or 4-position; R.sub.1 is C.sub.1 -C.sub.3 alkyl; R.sub.2 is C.sub.1 -C.sub.7 alkyl, optionally hydroxy-substituted on at least one of its second to seventh carbon, or C.sub.3 -C.sub.7 cycloalkyl, optionally hydroxy substituted, or C.sub.3 -C.sub.7 cycloalkylmethyl; or R.sub.1 and R.sub.2 can, together with the nitrogen therebetween, be a 4- to 7-membered saturated monocyclic, heterocyclic ring which can optionally include an oxygen or N--CH.sub.3 ; R.sub.3 is hydrogen, chlorine, or methyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 is hydrogen, chlorine or C.sub.1 -C.sub.4 alkyl; and Z is a single bond, oxygen, methylene or 1,2-ethylene; and NR.sub.1 R.sub.2 --N oxides and nontoxic, pharmaceutically acceptable addition salts thereof. Also disclosed are pyrrolobenzodiazepinone intermediates, pharmaceutical compositions containing the condensed diazepinones and methods of using them to treat cardiovascular disorders, particularly bradycardia and bradyarrhythmia.

  揭示了式I的新型缩合二氮杂环酮##STR1##其中B是从##STR2##中选择的融合环；X是--CH--或者当B是邻苯二甲烷时，X也可以是氮；A.sub.1是C.sub.1-C.sub.2烷基；A.sub.2是C.sub.1-C.sub.2，当它相对于饱和杂环环氮位于2位时，或者是单键或亚甲基，当它位于3位或4位时；R.sub.1是C.sub.1-C.sub.3烷基；R.sub.2是C.sub.1-C.sub.7烷基，其至少在第二到第七碳上可选择地被羟基取代，或者是C.sub.3-C.sub.7环烷基，可选择地被羟基取代，或者是C.sub.3-C.sub.7环烷基甲基；或者R.sub.1和R.sub.2可以与其之间的氮一起形成一个4到7成员的饱和单环杂环，可选择地包括氧或N--CH.sub.3；R.sub.3是氢、氯或甲基；R.sub.4是氢或C.sub.1-C.sub.4烷基，R.sub.5是氢、氯或C.sub.1-C.sub.4烷基；Z是单键、氧、亚甲基或1,2-乙烯基；以及NR.sub.1 R.sub.2 --N氧化物和其无毒、药学上可接受的加合盐。还揭示了吡咯苯二氮杂环酮中间体、含有缩合二氮杂环酮的药物组合物以及使用它们治疗心血管疾病，特别是心动过缓和心动过缓性心律失常的方法。
• Condensed diazepinones, processes for preparing them and pharmaceutical
  申请人：Karl Thomae GmbH

  公开号：US05006522A1

  公开（公告）日：1991-04-09

  Novel condensed diazepinone of general formula I are described, ##STR1## wherein B represents one of the divalent groups ##STR2## and X.sup.1, X.sup.2, A.sup.1, A.sup.2 and R.sup.1 to R.sup.10 are as defined in herein useful as vagal pacemakers for treating bradycardia and bradyarrhythmia. The novel diazepinones also have spasmolytic properties on peripheral organs, antiemetic properties and are capable of promoting cerebral blood flow.

  描述了一种一般式I的新型缩合二氮杂环酮，其中B代表二价基团之一，X.sup.1、X.sup.2、A.sup.1、A.sup.2和R.sup.1到R.sup.10的定义如本文所述，可用作治疗心动过缓和心动过缓性心律失常的迷走神经节调节器。这种新型二氮杂环酮还具有对外周器官的解痉作用、抗恶心作用，并能促进脑血流。
• 5,11-dihydro-6H-pyrido(2,3-B)(1,4)benzodiazepin-6-ones substituted in
  申请人：Karl Thomae GmbH

  公开号：US04724236A1

  公开（公告）日：1988-02-09

  Compounds of general formula I are described, ##STR1## wherein X represents the group .dbd.CHR, .dbd.NR or an oxygen atom and A represents the groups --NR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 represent alkyl, cycloalkyl or phenylalkyl groups, n represents the number 0, 1 or 2, R.sup.3 represents a hydrogen atom, a hydroxy or alkyl group or a group --(CH.sub.2).sub.n --N--R.sup.5 R.sup.6 (R.sup.5 and R.sup.6 being lower alkyl groups) and R.sup.4 is an alkyl or phenylalkyl group; two processes for preparing these compounds and the salts thereof are also described. The compounds have favourable effects on heart rate and can be used as vagal pacemakers for treating bradycardia and bradyarrhythmia in human and veterinary medicine. Some of these compounds also have very good antithrombotic effects.

  通式I的化合物描述如下，其中X代表基团.dbd.CHR，.dbd.NR或氧原子，A代表基团--NR.sup.1 R.sup.2，其中R.sup.1和R.sup.2代表烷基、环烷基或苯基烷基基团，n代表数字0、1或2，R.sup.3代表氢原子、羟基或烷基基团或基团--(CH.sub.2).sub.n --N--R.sup.5 R.sup.6（R.sup.5和R.sup.6为较低的烷基基团），R.sup.4是烷基或苯基烷基基团；还描述了制备这些化合物及其盐的两种方法。这些化合物对心率有良好的影响，并可用作治疗人类和兽医学中的心动过缓和心动过缓性心律失常的迷走神经起搏器。其中一些化合物还具有非常好的抗血栓作用。
• Substituted pyrido(2,3-B) (1,4) benzodiazepin-6-ones, and medicaments
  申请人：Karl Thomae GmbH

  公开号：US04971966A1

  公开（公告）日：1990-11-20

  New substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones suitable as vagal pacemakers for the treatment of bradycardias and bradyarrhythmias in human and veterinary medicine are described.

  描述了适用于治疗人类和兽医学中窦性心动过缓和缓慢性心律失常的迷走神经起搏器的新取代吡啶并[2,3-b][1,4]苯并二氮杂卓-6-酮。
• Indeno [1,2-c]pyrazol-4-ones and their uses
  申请人：——

  公开号：US20010027195A1

  公开（公告）日：2001-10-04

  The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1 that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

  本发明涉及合成一种新类别的indeno[1,2-c]pyrazol-4-ones化合物，其化学式为(I):1，这些化合物是一类名为细胞周期依赖性激酶的酶的强效抑制剂，与催化亚基cdk1-9及其调节亚基cyclins A-H有关。本发明还提供了一种新颖的治疗癌症或其他增生性疾病的方法，即通过给予这些化合物中的一种或其药用可接受的盐形式的治疗有效剂量。另外，可以通过给予本发明化合物之一与一种或多种其他已知的抗癌或抗增生剂的治疗有效组合来治疗癌症或其他增生性疾病。